These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

926 related articles for article (PubMed ID: 24439788)

  • 1. Overdiagnosis and overtreatment of prostate cancer.
    Loeb S; Bjurlin MA; Nicholson J; Tammela TL; Penson DF; Carter HB; Carroll P; Etzioni R
    Eur Urol; 2014 Jun; 65(6):1046-55. PubMed ID: 24439788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structured Population-based Prostate-specific Antigen Screening for Prostate Cancer: The European Association of Urology Position in 2019.
    Gandaglia G; Albers P; Abrahamsson PA; Briganti A; Catto JWF; Chapple CR; Montorsi F; Mottet N; Roobol MJ; Sønksen J; Wirth M; van Poppel H
    Eur Urol; 2019 Aug; 76(2):142-150. PubMed ID: 31092338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen.
    Vickers AJ; Sjoberg DD; Ulmert D; Vertosick E; Roobol MJ; Thompson I; Heijnsdijk EA; De Koning H; Atoria-Swartz C; Scardino PT; Lilja H
    BMC Med; 2014 Feb; 12():26. PubMed ID: 24512643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Screening for prostate cancer.
    Ilic D; Neuberger MM; Djulbegovic M; Dahm P
    Cochrane Database Syst Rev; 2013 Jan; 2013(1):CD004720. PubMed ID: 23440794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. From Screening to Mortality Reduction: An Overview of Empirical Data on the Patient Journey in European Randomized Study of Screening for Prostate Cancer Rotterdam After 21 Years of Follow-up and a Reflection on Quality of Life.
    Hogenhout R; Remmers S; van Slooten-Midderigh ME; de Vos II; Roobol MJ;
    Eur Urol Oncol; 2024 Aug; 7(4):713-720. PubMed ID: 37690917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overdiagnosis of prostate carcinoma by screening: an estimate based on the results of the Florence Screening Pilot Study.
    Zappa M; Ciatto S; Bonardi R; Mazzotta A
    Ann Oncol; 1998 Dec; 9(12):1297-300. PubMed ID: 9932159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate-Specific Antigen-Based Screening for Prostate Cancer: Evidence Report and Systematic Review for the US Preventive Services Task Force.
    Fenton JJ; Weyrich MS; Durbin S; Liu Y; Bang H; Melnikow J
    JAMA; 2018 May; 319(18):1914-1931. PubMed ID: 29801018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context.
    Draisma G; Etzioni R; Tsodikov A; Mariotto A; Wever E; Gulati R; Feuer E; de Koning H
    J Natl Cancer Inst; 2009 Mar; 101(6):374-83. PubMed ID: 19276453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate Cancer Screening.
    Catalona WJ
    Med Clin North Am; 2018 Mar; 102(2):199-214. PubMed ID: 29406053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative effectiveness of alternative prostate-specific antigen--based prostate cancer screening strategies: model estimates of potential benefits and harms.
    Gulati R; Gore JL; Etzioni R
    Ann Intern Med; 2013 Feb; 158(3):145-53. PubMed ID: 23381039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate cancer overdiagnosis and overtreatment.
    Klotz L
    Curr Opin Endocrinol Diabetes Obes; 2013 Jun; 20(3):204-9. PubMed ID: 23609043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement.
    ; Grossman DC; Curry SJ; Owens DK; Bibbins-Domingo K; Caughey AB; Davidson KW; Doubeni CA; Ebell M; Epling JW; Kemper AR; Krist AH; Kubik M; Landefeld CS; Mangione CM; Silverstein M; Simon MA; Siu AL; Tseng CW
    JAMA; 2018 May; 319(18):1901-1913. PubMed ID: 29801017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A European Model for an Organised Risk-stratified Early Detection Programme for Prostate Cancer.
    Van Poppel H; Hogenhout R; Albers P; van den Bergh RCN; Barentsz JO; Roobol MJ
    Eur Urol Oncol; 2021 Oct; 4(5):731-739. PubMed ID: 34364829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term projections of the harm-benefit trade-off in prostate cancer screening are more favorable than previous short-term estimates.
    Gulati R; Mariotto AB; Chen S; Gore JL; Etzioni R
    J Clin Epidemiol; 2011 Dec; 64(12):1412-7. PubMed ID: 22032753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 2022 Update on Prostate Cancer Epidemiology and Risk Factors-A Systematic Review.
    Bergengren O; Pekala KR; Matsoukas K; Fainberg J; Mungovan SF; Bratt O; Bray F; Brawley O; Luckenbaugh AN; Mucci L; Morgan TM; Carlsson SV
    Eur Urol; 2023 Aug; 84(2):191-206. PubMed ID: 37202314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trade-Off between Treatment of Early Prostate Cancer and Incidence of Advanced Prostate Cancer in the Prostate Screening Era.
    Shen X; Kumar P
    J Urol; 2016 May; 195(5):1397-1402. PubMed ID: 26656266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer overdiagnosis and overtreatment.
    Klotz L
    Curr Opin Urol; 2012 May; 22(3):203-9. PubMed ID: 22472510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Critical appraisal of prostate-specific antigen in prostate cancer screening: 20 years later.
    Pienta KJ
    Urology; 2009 May; 73(5 Suppl):S11-20. PubMed ID: 19375622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overdiagnosis and Lives Saved by Reflex Testing Men With Intermediate Prostate-Specific Antigen Levels.
    Gulati R; Morgan TM; A'mar T; Psutka SP; Tosoian JJ; Etzioni R
    J Natl Cancer Inst; 2020 Apr; 112(4):384-390. PubMed ID: 31225597
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 47.